Document is current
Any future updates will be listed below
-
Authors
Flores, Laura E.
Westmark, Danielle
Katz, Nicole B.
Hunter, Tracey L.
Silver, Emily M.
Bryan, Katherine M.
Jagsi, Reshma
McClelland, Shearwood III
Silver, Julie K.
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 15 December 2023
First Online: 5 January 2024
Declarations
:
: LEF, NBK, TLH, DW, KMB, SM3, JKS report no disclosures related to this work. Unrelated, JKS discloses that she participates in an advisory capacity for research funded by the National Institutes of Health as well as the Binational Scientific Foundation. She is a venture partner at Third Culture Capital. SM3 serves as a consultant for Gilmartin Capital, receives travel funding from GT Medical Technologies Inc., and receives research funding from the University Hospitals Minority Faculty Career Development Award, the ASTRO Emerging Investigator Award, the Robert Winn Diversity in Clinical Trials Career Development Award, and the National Cancer Institute Paul Calabresi K12 Clinical Oncology Research Career Development Program. RJ has stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from the Greenwall Foundation, Doris Duke Charitable Foundation, and the National Institutes of Health and grants or contracts for unrelated work from the National Institutes of Health, the Doris Duke Charitable Foundation, the American Cancer Society, the Greenwall Foundation, the Susan G. Komen Foundation, and Genentech. She has served as an expert witness for Kleinbard, LLC.
